{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:55:53Z","timestamp":1777280153332,"version":"3.51.4"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"DOI":"10.1007\/s11926-026-01220-4","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T06:46:57Z","timestamp":1777272417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treat-to-Target Urate-lowering Therapy: Lessons Learned from the STOP Gout Study"],"prefix":"10.1007","volume":"28","author":[{"given":"Ted R.","family":"Mikuls","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Helget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Newcomb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"O\u2019Dell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"2","key":"1220_CR1","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"1220_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273\u201382.","journal-title":"J Rheumatol"},{"issue":"23","key":"1220_CR3","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450\u201361.","journal-title":"N Engl J Med"},{"issue":"10156","key":"1220_CR4","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","volume":"392","author":"M Doherty","year":"2018","unstructured":"Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018;392(10156):1403\u201312.","journal-title":"Lancet"},{"issue":"10","key":"1220_CR5","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"1220_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","volume":"48","author":"HR Schumacher Jr.","year":"2009","unstructured":"Schumacher HR Jr., Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48(2):188\u201394.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1220_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr.","year":"2008","unstructured":"Schumacher HR Jr., Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540\u20138.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1220_CR8","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","volume":"76","author":"LK Stamp","year":"2017","unstructured":"Stamp LK, Chapman PT, Barclay M, Horne A, Frampton C, Tan P, et al. Allopurinol dose escalation to achieve serum urate below 6 mg\/dL: an open-label extension study. Ann Rheum Dis. 2017;76(12):2065\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1220_CR9","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1016\/S2665-9913(25)00165-1","volume":"7","author":"E Cipolletta","year":"2025","unstructured":"Cipolletta E, Nakafero G, Rozza D, Mahil SK, Smith CH, Riley RD, et al. Development and validation of a prognostic model for predicting the risk of allopurinol-induced severe cutaneous adverse reactions: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data. Lancet Rheumatol. 2025;7(12):e840\u201350.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"1220_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","volume":"17","author":"MJ Roughley","year":"2015","unstructured":"Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17(1):90.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"1220_CR11","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","volume":"175","author":"CY Yang","year":"2015","unstructured":"Yang CY, Chen CH, Deng ST, Huang CS, Lin YJ, Chen YJ, et al. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan. JAMA Intern Med. 2015;175(9):1550\u20137.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"1220_CR12","first-page":"165","volume":"21","author":"PK Gandhi","year":"2015","unstructured":"Gandhi PK, Gentry WM, Ma Q, Bottorff MB. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective. J Manag Care Spec Pharm. 2015;21(2):165\u201375.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"1220_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3111\/13696998.2015.1116990","volume":"19","author":"LJ Smolen","year":"2016","unstructured":"Smolen LJ, Gahn JC, Mitri G, Shiozawa A. Febuxostat in the management of gout: a cost-effectiveness analysis. J Med Econ. 2016;19(3):265\u201376.","journal-title":"J Med Econ"},{"issue":"6","key":"1220_CR14","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72(6):879\u201395.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1220_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"key":"1220_CR16","doi-asserted-by":"crossref","unstructured":"O'Dell JR, Brophy MT, Pillinger MH, Neogi T, Palevsky PM, Wu H, et al. Comparative effectiveness of allopurinol and febuxostat in gout management. NEJM Evid. 2022;1(3).","DOI":"10.1056\/EVIDoa2100028"},{"key":"1220_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cct.2018.03.015","volume":"68","author":"S Timilsina","year":"2018","unstructured":"Timilsina S, Brittan K, O\u2019Dell JR, Brophy M, Davis-Karim A, Henrie AM, et al. Design and rationale for the veterans affairs \u201cCooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat\u201d Trial. Contemp Clin Trials. 2018;68:102\u20138.","journal-title":"Contemp Clin Trials"},{"issue":"10","key":"1220_CR18","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789\u201398.","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"1220_CR19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018;378(13):1200\u201310.","journal-title":"N Engl J Med"},{"issue":"10264","key":"1220_CR20","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","volume":"396","author":"IS Mackenzie","year":"2020","unstructured":"Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745\u201357.","journal-title":"Lancet"},{"issue":"9","key":"1220_CR21","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/acr.24339","volume":"73","author":"LN Helget","year":"2021","unstructured":"Helget LN, England BR, Roul P, Sayles H, Petro AD, Michaud K, et al. Incidence, Prevalence, and Burden of Gout in the Veterans Health Administration. Arthritis Care Res (Hoboken). 2021;73(9):1363\u201371.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"1220_CR22","doi-asserted-by":"publisher","first-page":"e2142347","DOI":"10.1001\/jamanetworkopen.2021.42347","volume":"5","author":"TR Mikuls","year":"2022","unstructured":"Mikuls TR, Soto Q, Petro A, Helget L, Roul P, Sayles H, et al. Comparison of rates of lower extremity amputation in patients with and without gout in the US Department of Veterans Affairs Health System. JAMA Netw Open. 2022;5(1):e2142347.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1220_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13075-020-02260-6","volume":"22","author":"M Toprover","year":"2020","unstructured":"Toprover M, Shah B, Oh C, Igel TF, Romero AG, Pike VC, et al. Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study. Arthritis Res Ther. 2020;22(1):169.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1220_CR24","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/art.43259","volume":"77","author":"C Yokose","year":"2025","unstructured":"Yokose C, McCormick N, Lu N, Jiang B, Tan K, Chigurupati S, et al. Comparative cardiovascular safety of nonsteroidal anti-inflammatory drug versus colchicine use when initiating urate-lowering therapy among patients with gout: target trial emulations. Arthritis Rheumatol. 2025;77(12):1767\u201377.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"1220_CR25","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1053\/j.ajkd.2024.04.017","volume":"84","author":"LN Helget","year":"2024","unstructured":"Helget LN, Davis-Karim A, O\u2019Dell JR, Mikuls TR, Newcomb JA, Androsenko M, et al. Efficacy and safety of allopurinol and febuxostat in patients with gout and CKD: subgroup analysis of the STOP Gout Trial. Am J Kidney Dis. 2024;84(5):538\u201345.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1220_CR26","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/bcp.13516","volume":"84","author":"DFB Wright","year":"2018","unstructured":"Wright DFB, Dalbeth N, Phipps-Green AJ, Merriman TR, Barclay ML, Drake J, et al. The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool. Br J Clin Pharmacol. 2018;84(5):937\u201343.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1220_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.23876\/j.krcp.2017.36.3.274","volume":"36","author":"S Kim","year":"2017","unstructured":"Kim S, Kim HJ, Ahn HS, Oh SW, Han KH, Um TH, et al. Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis. Kidney Res Clin Pract. 2017;36(3):274\u201381.","journal-title":"Kidney Res Clin Pract"},{"issue":"1","key":"1220_CR28","doi-asserted-by":"publisher","first-page":"2332956","DOI":"10.1080\/07853890.2024.2332956","volume":"56","author":"XH Yang","year":"2024","unstructured":"Yang XH, Zhang BL, Cheng Y, Fu SK, Jin HM. Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials. Ann Med. 2024;56(1):2332956.","journal-title":"Ann Med"},{"issue":"2","key":"1220_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/pds.5127","volume":"30","author":"R Koto","year":"2021","unstructured":"Koto R, Nakajima A, Horiuchi H, Yamanaka H. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: a retrospective observational study of Japanese health insurance claims data. Pharmacoepidemiol Drug Saf. 2021;30(2):157\u201368.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"1220_CR30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3899\/jrheum.140588","volume":"42","author":"N Rashid","year":"2015","unstructured":"Rashid N, Coburn BW, Wu YL, Cheetham TC, Curtis JR, Saag KG, et al. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol. 2015;42(3):504\u201312.","journal-title":"J Rheumatol"},{"issue":"3","key":"1220_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3899\/jrheum.190522","volume":"47","author":"JA Singh","year":"2020","unstructured":"Singh JA, Yang S, Saag KG. Factors influencing the effectiveness of allopurinol in achieving and sustaining target serum urate in a US Veterans Affairs gout cohort. J Rheumatol. 2020;47(3):449\u201360.","journal-title":"J Rheumatol"},{"issue":"2","key":"1220_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","volume":"45","author":"MA Becker","year":"2015","unstructured":"Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, et al. An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015;45(2):174\u201383.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"1220_CR33","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/art.40486","volume":"70","author":"BW Coburn","year":"2018","unstructured":"Coburn BW, Michaud K, Bergman DA, Mikuls TR. Allopurinol dose escalation and mortality among patients with gout: a national propensity-matched cohort study. Arthritis Rheumatol. 2018;70(8):1298\u2013307.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"1220_CR34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.31128\/AJGP-04-19-4909","volume":"48","author":"LK Stamp","year":"2019","unstructured":"Stamp LK, Chapman P, Hudson B, Frampton C, Hamilton G, Judd A. The challenges of managing gout in primary care: results of a best-practice audit. Aust J Gen Pract. 2019;48(9):631\u20137.","journal-title":"Aust J Gen Pract"},{"issue":"4","key":"1220_CR35","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/art.42731","volume":"76","author":"LN Helget","year":"2024","unstructured":"Helget LN, O\u2019Dell JR, Newcomb JA, Androsenko M, Brophy MT, Davis-Karim A, et al. Determinants of achieving serum urate goal with treat-to-target urate-lowering therapy in gout. Arthritis Rheumatol. 2024;76(4):638\u201346.","journal-title":"Arthritis Rheumatol"},{"issue":"14","key":"1220_CR36","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","volume":"32","author":"RL Wortmann","year":"2010","unstructured":"Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32(14):2386\u201397.","journal-title":"Clin Ther"},{"issue":"Suppl 1","key":"1220_CR37","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/ar1908","volume":"8 Suppl 1","author":"BN Cronstein","year":"2006","unstructured":"Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther. 2006;8 Suppl 1(Suppl 1):S3.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"1220_CR38","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/rheumatology\/keu157","volume":"53","author":"A Latourte","year":"2014","unstructured":"Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology (Oxford). 2014;53(11):1920\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1220_CR39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12916-017-0922-5","volume":"15","author":"R Terkeltaub","year":"2017","unstructured":"Terkeltaub R. What makes gouty inflammation so variable? BMC Med. 2017;15(1):158.","journal-title":"BMC Med"},{"issue":"5","key":"1220_CR40","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.2022.11390","volume":"328","author":"E Cipolletta","year":"2022","unstructured":"Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Association between gout flare and subsequent cardiovascular events among patients with gout. JAMA. 2022;328(5):440\u201350.","journal-title":"JAMA"},{"issue":"3","key":"1220_CR41","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/S2665-9913(24)00248-0","volume":"7","author":"E Cipolletta","year":"2025","unstructured":"Cipolletta E, Nakafero G, McCormick N, Yokose C, Avery AJ, Mamas MA, et al. Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data. Lancet Rheumatol. 2025;7(3):e197\u2013207.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"1220_CR42","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/acr.25309","volume":"76","author":"D Maher","year":"2024","unstructured":"Maher D, Reeve E, Hopkins A, Tan JM, Tantiongco M, Ailabouni N, et al. Comparative Risk of Gout Flares When Initiating or Escalating Various Urate-Lowering Therapy: A Systematic Review With Network Meta-Analysis. Arthritis Care Res (Hoboken). 2024;76(6):871\u201381.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1220_CR43","doi-asserted-by":"crossref","unstructured":"Barry A, Helget LN, Androsenko M, Wu H, Kramer B, Newcomb JA, et al. Comparison of gout flares with the initiation of treat-to-target allopurinol and febuxostat: a post-hoc analysis of a randomized multicenter trial. Arthritis Rheumatol. 2024.","DOI":"10.1002\/art.42927"},{"issue":"3","key":"1220_CR44","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/art.40381","volume":"70","author":"AL Gaffo","year":"2018","unstructured":"Gaffo AL, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, et al. Brief report: validation of a definition of flare in patients with established gout. Arthritis Rheumatol. 2018;70(3):462\u20137.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1220_CR45","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/acr.25486","volume":"77","author":"LK Stamp","year":"2025","unstructured":"Stamp LK, Frampton C, Newcomb JA, O\u2019Dell JR, Mikuls TR, Dalbeth N. Gout flares after stopping anti-inflammatory prophylaxis: a rapid literature review and meta-analysis. Arthritis Care Res (Hoboken). 2025;77(6):720\u20136.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"1220_CR46","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/rheumatology\/ket265","volume":"52","author":"P Chandratre","year":"2013","unstructured":"Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD. Health-related quality of life in gout: a systematic review. Rheumatology (Oxford). 2013;52(11):2031\u201340.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1220_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3111\/13696998.2010.540874","volume":"14","author":"NL Edwards","year":"2011","unstructured":"Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14(1):10\u20135.","journal-title":"J Med Econ"},{"issue":"4","key":"1220_CR48","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/rheumatology\/keq346","volume":"50","author":"PP Khanna","year":"2011","unstructured":"Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford). 2011;50(4):740\u20135.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1220_CR49","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3899\/jrheum.090370","volume":"36","author":"HR Schumacher","year":"2009","unstructured":"Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, et al. Outcome domains for studies of acute and chronic gout. J Rheumatol. 2009;36(10):2342\u20135.","journal-title":"J Rheumatol"},{"issue":"5","key":"1220_CR50","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1186\/ar4281","volume":"15","author":"CA Scire","year":"2013","unstructured":"Scire CA, Manara M, Cimmino MA, Govoni M, Salaffi F, Punzi L, et al. Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther. 2013;15(5):R101.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1220_CR51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2017-212063","volume":"77","author":"V Sigurdardottir","year":"2018","unstructured":"Sigurdardottir V, Drivelegka P, Sv\u00e4rd A, Jacobsson LTH, Dehlin M. Work disability in gout: a population-based case-control study. Ann Rheum Dis. 2018;77(3):399\u2013404.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1220_CR52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/acr.25618","volume":"78","author":"A Barry","year":"2026","unstructured":"Barry A, England BR, Sayles H, Helget LN, Androsenko M, Wu H, et al. Improvements in health-related quality of life with treat-to-target urate-lowering therapy in gout: a post hoc analysis of a randomized multicenter trial. Arthritis Care Res (Hoboken). 2026;78(2):259\u201369.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"1220_CR53","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3899\/jrheum.111375","volume":"39","author":"V Strand","year":"2012","unstructured":"Strand V, Khanna D, Singh JA, Forsythe A, Edwards NL. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol. 2012;39(7):1450\u20137.","journal-title":"J Rheumatol"},{"issue":"12","key":"1220_CR54","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1093\/rheumatology\/kead124","volume":"62","author":"T Uhlig","year":"2023","unstructured":"Uhlig T, Karoliussen LF, Sexton J, Provan SA, Kvien TK, Haavardsholm EA, et al. Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study. Rheumatology (Oxford). 2023;62(12):3886\u201392.","journal-title":"Rheumatology (Oxford)"},{"key":"1220_CR55","doi-asserted-by":"publisher","first-page":"152800","DOI":"10.1016\/j.semarthrit.2025.152800","volume":"74","author":"S Kohn","year":"2025","unstructured":"Kohn S, Sayles H, Helget LN, England BR, Roul P, Newcomb JA, et al. Real-world persistence of urate-lowering therapy following a treat-to-target intervention: A two-year follow-up analysis of the STOP gout trial. Semin Arthritis Rheum. 2025;74:152800.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1220_CR56","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/BOR.0000000000000996","volume":"36","author":"LN Helget","year":"2024","unstructured":"Helget LN, Mikuls TR. Health disparities in gout. Curr Opin Rheumatol. 2024;36(2):120\u20135.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"1220_CR57","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13075-022-02852-4","volume":"24","author":"M Guma","year":"2022","unstructured":"Guma M, Dadpey B, Coras R, Mikuls TR, Hamilton B, Quehenberger O, et al. Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes. Arthritis Res Ther. 2022;24(1):175.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1220_CR58","doi-asserted-by":"publisher","first-page":"24598","DOI":"10.1038\/s41598-024-74154-5","volume":"14","author":"C Sanchez","year":"2024","unstructured":"Sanchez C, Campeau A, Liu-Bryan R, Mikuls TR, O\u2019Dell JR, Gonzalez DJ, et al. Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators. Sci Rep. 2024;14(1):24598.","journal-title":"Sci Rep"},{"key":"1220_CR59","doi-asserted-by":"crossref","unstructured":"Wheeler AM, Ourada TJ, Jones SQ, Duryee MJ, England BR, Reynolds RJ, et al. Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapy. Rheumatology (Oxford). 2025.","DOI":"10.1093\/rheumatology\/keaf680"},{"key":"1220_CR60","doi-asserted-by":"publisher","first-page":"1776479","DOI":"10.3389\/fimmu.2026.1776479","volume":"17","author":"K Wang","year":"2026","unstructured":"Wang K, Li J, Li J, Zeng F, Li S, Chen P, et al. Spatiotemporal immune gradients in gout: immune response-driven activation of the NLRP3-IL-1beta axis and its transition to trained immunity. Front Immunol. 2026;17:1776479.","journal-title":"Front Immunol"},{"issue":"3","key":"1220_CR61","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/art.37822","volume":"65","author":"S Steiger","year":"2013","unstructured":"Steiger S, Harper JL. Neutrophil cannibalism triggers transforming growth factor beta1 production and self regulation of neutrophil inflammatory function in monosodium urate monohydrate crystal-induced inflammation in mice. Arthritis Rheum. 2013;65(3):815\u201323.","journal-title":"Arthritis Rheum"},{"issue":"26","key":"1220_CR62","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.3748\/wjg.v13.i26.3540","volume":"13","author":"K Qureshi","year":"2007","unstructured":"Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2007;13(26):3540\u201353.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"1220_CR63","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1042\/BCJ20190468","volume":"477","author":"A Yang","year":"2020","unstructured":"Yang A, Mottillo EP. Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics. Biochem J. 2020;477(5):985\u20131008.","journal-title":"Biochem J"},{"key":"1220_CR64","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","volume":"10","author":"F Zatterale","year":"2019","unstructured":"Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol. 2019;10:1607.","journal-title":"Front Physiol"},{"issue":"1","key":"1220_CR65","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13075-019-2016-6","volume":"21","author":"RK Narang","year":"2019","unstructured":"Narang RK, Vincent Z, Phipps-Green A, Stamp LK, Merriman TR, Dalbeth N. Population-specific factors associated with fractional excretion of uric acid. Arthritis Res Ther. 2019;21(1):234.","journal-title":"Arthritis Res Ther"},{"key":"1220_CR66","doi-asserted-by":"crossref","unstructured":"Nica V, Gaal O, Badii M, Cabau G, Mirea AM, Hotea I, et al. Gout risk allele regulating IRF5 expression is associated with enhanced IL-1beta production in response to palmitate and monosodium urate crystals. Int J Mol Sci. 2025;26(20).","DOI":"10.3390\/ijms26209930"},{"issue":"9","key":"1220_CR67","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3899\/jrheum.180855","volume":"46","author":"BM Alberts","year":"2019","unstructured":"Alberts BM, Barber JS, Sacre SM, Davies KA, Ghezzi P, Mullen LM. Precipitation of soluble uric acid is necessary for in vitro activation of the NLRP3 inflammasome in primary human monocytes. J Rheumatol. 2019;46(9):1141\u201350.","journal-title":"J Rheumatol"},{"key":"1220_CR68","doi-asserted-by":"publisher","first-page":"39884","DOI":"10.1038\/srep39884","volume":"7","author":"TT Braga","year":"2017","unstructured":"Braga TT, Forni MF, Correa-Costa M, Ramos RN, Barbuto JA, Branco P, et al. Soluble uric acid activates the NLRP3 inflammasome. Sci Rep. 2017;7:39884.","journal-title":"Sci Rep"},{"issue":"4","key":"1220_CR69","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/annrheumdis-2014-206564","volume":"75","author":"TO Crisan","year":"2016","unstructured":"Crisan TO, Cleophas MC, Oosting M, Lemmers H, Toenhake-Dijkstra H, Netea MG, et al. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann Rheum Dis. 2016;75(4):755\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"1220_CR70","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1073\/pnas.1620910114","volume":"114","author":"TO Crisan","year":"2017","unstructured":"Crisan TO, Cleophas MCP, Novakovic B, Erler K, van de Veerdonk FL, Stunnenberg HG, et al. Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway. Proc Natl Acad Sci U S A. 2017;114(21):5485\u201390.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-026-01220-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-026-01220-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-026-01220-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:03:09Z","timestamp":1777276989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-026-01220-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1007\/s11926-026-01220-4","relation":{},"ISSN":["1534-6307"],"issn-type":[{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies with human subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"TRM has had prior research support from Horizon Therapeutics (Amgen) and has served as a paid consultant for Horizon, Merck, Olatec Therapeutics, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Dr. Mikuls has had prior research support from Horizon Therapeutics (Amgen) and has served as a paid consultant for Horizon, Merck, Olatec Therapeutics, and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"13"}}